Literature DB >> 8310856

Monitoring of jugular venous oxygen saturation in comatose patients with subarachnoid haemorrhage and intracerebral haematomas.

A von Helden1, G H Schneider, A Unterberg, W R Lanksch.   

Abstract

To prevent secondary cerebral ischemia in comatose patients it would be of great importance to assess cerebral blood flow. Recently monitoring of the jugular venous oxygen saturation (SJVO2) has been shown to continuously evaluate cerebral oxygenation and to estimate cerebral blood flow. While most of these studies have dealt with severely head injured patients, we investigated cerebral oxygenation in 50 comatose patients due to an intracerebral haematoma (n = 14), subarachnoid haemorrhage (n = 12) and severe head injury (n = 24). In these groups of patients, the reaction of SJVO2 to hyperventilation and to lowering of blood pressure was studied. Moderate hyperventilation from 35 to 28 mmHg resulted in a significant decrease of SJVO2 in all groups. A critical SJVO2 between 50 and 55% was found in one half of the patients studied, a pathological SJVO2 below 50% was seen in 23% of the cases. Lowering of arterial blood pressure within the limits of autoregulation resulted in decreases of SJVO2 in patients with intracerebral haematomas only. 55% of these patients showed signs of insufficient cerebral oxygenation. Furthermore the frequency of spontaneous desaturation episodes was studied retrospectively and comparison made between the different groups. These episodes were found more frequently in patients with intracerebral haematomas compared to patients with severe head injury. In conclusion, monitoring of jugular venous oxygen saturation is a valuable tool for detecting and treating insufficient cerebral oxygenation in comatose patients following intracerebral haemorrhage, subarachnoid haemorrhage and severe head injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8310856     DOI: 10.1007/978-3-7091-9302-0_18

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  9 in total

1.  Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury.

Authors:  Saef Izzy; Susanne Muehlschlegel
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

2.  Emergency treatment options for pediatric traumatic brain injury.

Authors:  J Exo; C Smith; R Smith; Mj Bell
Journal:  Ped Health       Date:  2009

3.  Secondary decline of cerebral autoregulation is associated with worse outcome after intracerebral hemorrhage.

Authors:  Matthias Reinhard; Florian Neunhoeffer; Thomas A Gerds; Wolf-Dirk Niesen; Klaus-Juergen Buttler; Jens Timmer; Bernhard Schmidt; Marek Czosnyka; Cornelius Weiller; Andreas Hetzel
Journal:  Intensive Care Med       Date:  2009-10-17       Impact factor: 17.440

4.  Continuous monitoring of jugular bulb oxygen saturation in comatose patients--therapeutic implications.

Authors:  G H Schneider; A von Helden; W R Lanksch; A Unterberg
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Hyperventilation in neurological patients: from physiology to outcome evidence.

Authors:  Zhong Zhang; Qulian Guo; E Wang
Journal:  Curr Opin Anaesthesiol       Date:  2019-10       Impact factor: 2.706

Review 6.  Hyperventilation in Adult TBI Patients: How to Approach It?

Authors:  Elisa Gouvea Bogossian; Lorenzo Peluso; Jacques Creteur; Fabio Silvio Taccone
Journal:  Front Neurol       Date:  2021-01-28       Impact factor: 4.003

Review 7.  Monitoring of brain and systemic oxygenation in neurocritical care patients.

Authors:  Mauro Oddo; Julian Bösel
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

8.  Evidence-based cerebral vasospasm surveillance.

Authors:  Heather Kistka; Michael C Dewan; J Mocco
Journal:  Neurol Res Int       Date:  2013-06-03

Review 9.  Pro/con debate: should PaCO2 be tightly controlled in all patients with acute brain injuries?

Authors:  Stephanie L Go; Jeffrey M Singh
Journal:  Crit Care       Date:  2013-01-29       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.